DrugDashboards

Meropenem

Meropenem · MEROPENEM 1 g/30mL · Injection, Powder, For Solution · Intravenous · Sagent Pharmaceuticals

NDC 25021-0161-30 · 10 VIAL in 1 CARTON / 30 mL in 1 VIAL · ANDA · View full market →

The short version

8 companies supply this market — a reasonable cushion if one runs into trouble. Historically, drugs in this position went on to a new shortage within 90 days about 0.4% of the time — roughly 3× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed
$57.40
Reported to Texas DSHS · 2026 annual filing · Sagent

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.4%chance of a new FDA shortage posting for meropenem (injectable) in the next 90 days

sterile injectable · OAI inspection at a producing facility (24 months) · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is 3× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $185.36 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA216424
TE code
AP
Approval date
Jul 22, 2024
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Meropenem (Injection, Powder, For Solution)

LabelerStrengthFirst seenLast seen
Fresenius Kabi USA, LLCMEROPENEM 1 g/20mLJul 15, 2026Sep 3, 2026
Hikma Pharmaceuticals USA Inc.MEROPENEM 500 mg/10mLAug 13, 2026Sep 3, 2026
Hikma Pharmaceuticals USA Inc.MEROPENEM 1 g/20mLAug 13, 2026Sep 3, 2026
Hospira, Inc.MEROPENEM 500 mg/10mLJul 15, 2026Sep 3, 2026
Amneal Pharmaceuticals LLCMEROPENEM 500 mg/20mLJul 15, 2026Sep 2, 2026
Amneal Pharmaceuticals LLCMEROPENEM 1 g/30mLJul 15, 2026Sep 2, 2026
Eugia US LLCMEROPENEM 500 mg/1Jul 15, 2026Sep 2, 2026
Eugia US LLCMEROPENEM 1 g/1Jul 15, 2026Sep 2, 2026
Fresenius Kabi USA, LLCMEROPENEM 500 mg/10mLJul 15, 2026Sep 2, 2026
Sagent PharmaceuticalsMEROPENEM 1 g/30mLJul 15, 2026Sep 2, 2026
Sagent PharmaceuticalsMEROPENEM 500 mg/20mLJul 15, 2026Sep 2, 2026
WG Critical Care, LLCMEROPENEM 2 g/1Jul 15, 2026Sep 2, 2026
Xellia Pharmaceuticals USA LLCMEROPENEM 500 mg/1Jul 15, 2026Sep 2, 2026
Xellia Pharmaceuticals USA LLCMEROPENEM 1 g/1Jul 15, 2026Sep 2, 2026
Hospira, Inc.MEROPENEM 1 g/20mLJul 15, 2026Aug 31, 2026
WG Critical Care, LLCMEROPENEM 500 mg/1Jul 15, 2026Aug 28, 2026
WG Critical Care, LLCMEROPENEM 1 g/1Jul 15, 2026Aug 28, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Meropenem — NDC 25021-0161-30," retrieved September 3, 2026, https://drugdashboards.com/drug/25021016130.

Free to cite with attribution — see how the data is put together.